tbuckley/cabot-search huggingface dataset:
Abstract 13327: Prediction of Upcoming Therapeutic Episodes of ICD Through Routine Data in Routine Device Clinic of ICD Patients
Authors: Tamami Fujiishi, Shinichi Niwano, Masami Murakami, Hironori Nakamura, Tazuru Igarashi, Naruya Ishizue, Jun Oikawa, Jun Kishihara, Hidehira Fukaya, Hiroe Niwano, Junya Ako
Journal: Circulation (2015)

Background: Although implantable cardioverter-defibrillator (ICD) prevents sudden death of patients with life-threatening arrhythmia, prediction of upcoming ICD therapy, if possible, would be an important issue in device management. In the present study, the relationship between ICD therapeutic episodes and preceding routine device data was evaluated to clarify the predictors for ICD actuation in near future. Methods: The study population consisted of 100 consecutive ICD patients. All patients were followed up in the device clinic in every 4-month period, and their total follow-up periods of 22.8±4.1 months were divided into 734 4-month observation windows. The common data in device clinic including 12-lead ECG, chest X-ray, and interrogated device data were compared between patients with and without ICD therapeutic episodes during upcoming 4-month windows. To avoid inappropriate weighting on data of specific cases, such as unusual data in cases with frequent shock therapy, sampling number was limited 4-8 times in one case, and all data were evaluated as change during preceding 4 months, e.g., QTc calculated by subtracting 4 month preceding QTc from the recent QTc. Results: During 3.2±1.3 month follow-up, among 734 observation windows, appropriate and inappropriate ICD therapies appeared in 54 (ATP: 29, shock: 25) and 20 (ATP: 11, shock: 9) windows. When the patients were divided into spontaneous rhythm and paced-rhythm groups (n=558 and 170), spontaneous rhythm group did not show any significant difference in parameters between the windows with and without therapeutic episodes. In contrast in paced-rhythm group, RV lead impedance was significantly lower in the windows with therapeutic episodes in comparison with those without (-19.8±43.5Ω vs. 7.4±44.7Ω, p=0.047). Conclusions: Upcoming ICD therapy in near future might be able to be predicted by change in RV lead impedance at least in cases with paced-rhythm in ICD patients. It might reflect the electrical instability in cases with ICD therapeutic episodes.
Antisubstitution Laws
Authors: David W. Duhme
Journal: JAMA (1973)

<h3>To the Editor.—</h3> I must object to the logic employed in Dr. Schiffman's recent EDITORIAL supporting antisubstitution laws<sup>1</sup>and in the Joint Statement on Antisubstitution Laws and Regulations<sup>2</sup>in the same issue. The essence of their argument is that a physician is better suited than a pharmacist to specify the brand of a drug to be used. The factors that should enter into choosing a brand of drug are assurance of adequate quality (usually supplied by the Food and Drug Administration) and comparative shopping to find the lowest price. The Joint Statement says, "Since drug product selection entails knowledge derived from clinical experience, the physician's role in product selection remains primary." No physician's clinical experience is adequate to make valid distinctions between different brands of the same drug! Dr. Schiffman says, "Without automatic and absolute control over the exact regimen of therapy, the physician cannot possibly utilize all
Clarification
Authors: B W. Franklin Bishop
Journal: JAMA (1964)

<h3>To the Editor:—</h3> May attention has been drawn to letters inThe Journalof Nov 23, 1963 (<b>186</b>:805) commenting on a news item entitled "Radiotherapy Belongs to History," which appeared inThe Journal(<b>186</b>, Oct 26, 1963, adv p 35). I do not know where you obtained the information for your news item. This paper has never been published with my authority or consent. This paper was read at the Medical Congress in Johannesburg in July, 1963, but not by myself. My original lecture was to have been a slide demonstration with a draft to assist me in commenting on my slides, and it was not in any way fit or meant for publication. Unfortunately I was taken ill the night before and was not able to present it myself. In spite of my requesting that the lecture be canceled, the draft was given to someone to read without
Mouse Offspring Fail to Suffer After Mutagenic Radiation to Parent
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers
Authors: E. Karapanagiotou, H. S. Pandha, G. Hall, J. Chester, A. Melcher, M. Coffey, J. de Bono, M. E. Gore, C. M. Nutting, K. J. Harrington
Journal: Journal of Clinical Oncology (2009)

e14519 Background: Reolysin, a wild type reovirus (Dearing strain), replicates preferentially in Ras-activated cancer cells. Preclinical data have demonstrated synergistic tumor kill when reolysin is combined with standard chemotherapies including platinum agents and taxanes, justifying the clinical evaluation of this drug combination. Methods: Pts were initially treated in an open-label, dose-escalating, phase I trial and received iv reolysin, d1–5, iv carboplatin (AUC5), d1, and paclitaxel (175mg/m 2 ), d1, qw3. Reolysin was administered at a starting dose of 3x10 9 TCID 50 and then increased to 1x10 10 and 3x10 10 TCID 50 in cohorts of 3 pts. Primary endpoints for the dose escalation trial were to determine the maximum tolerated dose, dose limiting toxicity (DLT) and to recommend a dose for phase II studies. Secondary endpoints were to evaluate pharmacokinetics, immune response and anti-tumour activity. The primary endpoint for the phase II expansion cohort in head and neck (H&amp;N) pts is to characterize response rate. Results: 17 heavily pre-treated pts (11 M, median age 55 yrs) with advanced cancer: H&amp;N (10), melanoma (4), peritoneal/endometrial cancer (2), and sarcoma (1) have received 82 cycles of treatment to date; 4 pts are still on study. There were no DLTs in the dose escalation. Toxicities were mainly grade 1 and 2 and included: nausea, fatigue, vomiting, myalgia, fever, neutropenia, lymphopenia, thrombocytopenia and hypotension. This combination resulted in a blunting of antiviral immune response as compared to monotherapy virus. Response rates in 15 evaluable patients were partial response (PR) (4 pts), stable disease (SD) (6 pts) and progressive disease (5 pts). Of note, all PRs and 4/5 SDs were in H&amp;N disease. Conclusions: The combination of reolysin and carboplatin/paclitaxel was well tolerated and resulted in disease control in the majority of pts. Significant responses in refractory H&amp;N pts recommended this combination for phase II evaluation. Enrollment is ongoing and randomized studies are planned. [Table: see text]
Human Rabies-- Quebec, Canada, 2000
Journal: JAMA (2001)

On September 22, 2000, a 9-year-old boy awoke with a fever and complained of pain in his upper left arm. The pain persisted, and he developed insomnia and tremors in his arm and hand. He was admitted to a local hospital on September 27. That evening, he had mild dysphagia, pruritus of his upper chest and back, and a transient macular rash. On September 28, he developed tremors and myoclonic jerks in both arms, had become agitated, and had hydrophobia, aerophobia, dysarthria, and visual hallucinations. The next day hypersalivation was observed and the tremors and myoclonus had spread to his lower extremities. He became very anxious, indicated that he was suffocating, and underwent endotracheal intubation. A diagnosis of rabies was considered and he was transferred to a children's hospital. Laboratory findings were normal except a mildly elevated cerebral spinal fluid protein. An electroencephalogram form indicated no epileptiform activity. Head magnetic resonance imaging was normal. On September 29, the results of the rabies tests were positive, and rabies immune globulin and vaccine were administered to the patient. His neurologic and hemodynamic status deteriorated, and he died on October 6.
Acquired Spondylolysis After Spinal Fusion
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
On the Diagnosis of Incipient Tuberculization of the Lungs
Authors: W. H. Ranking
Journal: BMJ (1844)

l-Glutamate (Glu) activates at least eight different G protein-coupled receptors known as metabotropic glutamate (mGlu) receptors, which mostly act as regulators of synaptic transmission. These receptors consist of two domains: an extracellular domain in which agonists bind and a transmembrane heptahelix region involved in G protein activation. Although new mGlu receptor agonists and antagonists have been described, few are selective for a single mGlu subtype. Here, we have examined the effects of a novel compound, BAY36-7620 [(3a<i>S</i>,6a<i>S</i>)- 6a-Naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopental[<i>c</i>]furan-1-on], on mGlu receptors (mGlu1–8), transiently expressed in human embryonic kidney 293 cells. BAY36-7620 is a potent (IC<sub>50</sub> = 0.16 μM) and selective antagonist at mGlu1 receptors and inhibits &gt;60% of mGlu1a receptor constitutive activity (IC<sup>50</sup> = 0.38 μM). BAY36-7620 is therefore the first described mGlu1 receptor inverse agonist. To address the mechanism of action of BAY36-7620, Glu dose-response curves were performed in the presence of increasing concentrations of BAY36-7620. The results show that BAY36-7620 largely decreases the maximal effect of Glu. Moreover, BAY36-7620 did not displace the [<sup>3</sup>H]quisqualate binding from the Glu-binding pocket, further indicating that BAY36-7620 is a noncompetitive mGlu1 antagonist. Studies of chimeric receptors containing regions of mGlu1 and regions of DmGluA, mGlu2, or mGlu5, revealed that the transmembrane region of mGlu1 is necessary for activity of BAY36-7620. Transmembrane helices 4 to 7 are shown to play a critical role in the selectivity of BAY36-7620. This specific site of action of BAY36-7620 differs from that of competitive antagonists and indicates that the transmembrane region plays a pivotal role in the agonist-independent activity of this receptor. BAY36-7620 will be useful to further delineate the functional importance of the mGlu1 receptor, including its putative agonist-independent activity.
Coxsackievirus B1 peritonitis in a Patient Treated with Continuous Ambulatory Peritoneal Dialysis. A Case Report and Brief Review of the Literature.
Authors: Steven Pauwels, Bart De Moor, Koen Stas, Koen Magerman, Inge C. Gyssens, Marc Van Ranst, Reinoud Cartuyvels
Journal: Clinical Microbiology and Infection (2011)
John Hammerton
Authors: Tony Jackson
Journal: BMJ (2006)

Paediatrician who became a pioneer in the management of cystic fibrosisTony Jackson made a considerable contribution to the transformation of cystic fibrosis from a fatal disease of infancy to a chronic disease of adults.He applied the developing technology and pharmaceutical developments to everyday practice, supported families and patients, and, after retirement, gave strategic direction to the Cystic Fibrosis Trust research and medical advisory committee, of which he was chairman.The trust awarded him its John Panchaud medal.
Physicians’ Experiences With Impaired Colleagues
Authors: Joan M. Brewster
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment differences and other prognostic factors related to breast cancer survival. Delivery systems and medical outcomes
Authors: A. Lee-Feldstein
Journal: JAMA (1994)

<h3>Objective.</h3> —To determine differences in and relative importance of treatment modalities by hospital type and their effect on survival of breast cancer patients. <h3>Design.</h3> —Cohort of population-based cancer registry breast cancer patients diagnosed from 1984 through 1990. The analysis was done within this cohort, stratified by hospital type and treatment modality. <h3>Setting.</h3> —Orange County, California, residents diagnosed and treated for breast cancer in 126 hospitals (small community, large community, health maintenance organization [HMO], or teaching). <h3>Patients.</h3> —A total of 5892 non-Hispanic white women with no known prior cancer and with localized or regional, histologically confirmed breast cancer. <h3>Main Outcome Measures.</h3> —Effects of treatment modality and hospital type on survival. Adjustments for differences in age, tumor size, number of positive lymph nodes, and histology were included in the analysis. <h3>Results.</h3> —Use of recommended breast-conserving surgery (BCS) was greatest among teaching hospitals, where more than 50% of patients with localized disease received BCS between 1988 and 1990 and 40% to 50% with regional disease received BCS between 1984 and 1990. At nonteaching hospitals, 30% or less of patients received BCS between 1984 and 1989, regardless of stage. Rates of survival after BCS were at least as good as rates of survival after total mastectomy, other factors being equal. Survival rates varied by hospital type for patients with localized disease, with significantly better rates at large community hospitals and significantly worse rates at HMO hospitals in comparison with small hospitals. Patients with regional disease at large hospitals had a significant survival advantage. <h3>Conclusions.</h3> —Greater use of BCS is strongly urged. Overall, large community hospitals had significantly better survival rates than small community and HMO hospitals. Further follow-up will determine if treatment and survival differences by hospital type persist. (<i>JAMA</i>. 1994;271:1163-1168)
At US Army and Air Force bases in Europe, babies and broken bones head medical care list
Authors: M. F. Goldsmith
Journal: JAMA (1989)

WHAT WITH delivering thousands of babies a year, caring for family members with physical and mental disabilities, rehabilitating adults with alcohol and/or drug abuse problems, counseling couples with marital woes, and dealing with the various ailments and injuries that can afflict a basically healthy young population, it's cause for wonder that peacetime personnel at the US Army and US Air Force medical centers in West Germany are able effectively to carry out the other half of their mission: being prepared to provide medical support in the event of war. Visits to the two centers under the Heidelberg-based Seventh Medical Command, Frankfurt Army Regional Medical Center (FARMC) and Landstuhl Army Regional Medical Center (LARMC), and to the Wiesbaden Air Force Regional Medical Center give some idea how they do it. The task is clearly immense. All three are responsible for primary and tertiary care in their own approximately 13 000 km
Relationship Between Sleep Duration and Incident Coronary Artery Calcification—Reply
Authors: Diane S. Lauderdale
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The management of atrial fibrillation: summary of updated NICE guidance
Journal: BMJ (2014)

The management of atrial fibrillation: summary of updated NICE guidanceAddition-NICE has produced a Patient Decision Aid to be used alongside the guideline (BMJ 2014;348:g3655, doi:10.1136/bmj.g3655).It is designed to help patients weigh up the possible benefits, harms, advantages, and disadvantages of the different options for treatment, so that they can better discuss them with a health professional and come to a decision together.The PDA includes a tool for patients to rate what is and isn't important to them in stroke prevention.It also has visual representations of the risks and benefits of the treatments to prevent stroke.
Regeneration.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heart Defect
Authors: C. Scott Williams
Journal: Annals of Internal Medicine (2008)

Ad Libitum7 October 2008Heart DefectC. Scott Williams, MDC. Scott Williams, MDFrom Huntsville, AL 35801.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-7-200810070-00009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Hush now—just for a moment,My once intimate stranger,Let me listen to your heart.Let me touch your chest andSearch for distant sounds …The gallop or forgotten rub.Let me unbutton your blouseAnd press my hand againstThe thrill that vibrates beneath,Yearning to be rediscovered.Let me quiet the murmur thatWhispers the myriad reasons whyYou cannot love me anymore. Author, Article, and Disclosure InformationAffiliations: From Huntsville, AL 35801.Current Author Address: C. Scott Williams, MD, 420 Lowell Drive, Suite 107, Huntsville, AL 35801. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 October 2008Volume 149, Issue 7Page: 490KeywordsHeartThoraxTouch ePublished: 7 October 2008 Issue Published: 7 October 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Miscellany
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal